Advice
Following a full submission.
Risperidone is accepted for use within NHS Scotland for the treatment of episodes of mania in bipolar disorder.
Risperidone has similar efficacy to haloperidol in improving symptom scores, with fewer extrapyramidal side effects. In an economic model based on indirect comparison, monotherapy with risperidone appears to be cost-effective. No evidence is submitted on its cost-effectiveness profile in co-therapy.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Risperidone (Risperdal®)
- SMC ID:
- 113/04
- Indication:
- Mania in bipolar disorder
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 August 2004